ANALYSTS UPGRADE WITH $28 TAGRGET
H.C. Wainwright analyst Yi Chen started Bio-Path Holdings with a Buy rating and $28 price target. The company possesses an "intriguing" technology platform, DNAbilize, consisting of a novel and proprietary way to achieve sustainable systemic delivery of antisense oligonucleotides, Chen tells investors in a research note. Further,...
Stock picking has no certainties and often the greatest signals are from whispers among the investment community. Bi-Path Holdings has had quite a lot of good news recently that has brought it to the attention of many investors. Despite this we think that the price is gearing up for a significant move upwards, so we have alerts set on price and RSI spikes. This is...
Bio-Path released updated Phase 2 data for its lead candidate prexigebersen, codenamed BP1001, for treating acute myeloid leukemia, or AML, and also divulged a plan of action for taking the compound through clinical development toward registration.
Updated data from the Stage 1 of the Phase 2 study that evaluated the efficacy and safety of prexigebersen in...
Plan is to profit a 30% stake on this one.
Im in @ 0.65 today. My limit-order is allready place.
This is the right time to entre!
I will try to hold this one till next MPP GREEN FRIDAY! But sell it today take profit and monday we will see it again.
Never Ever hold a stock true weekend. is to risky!
Good luck traders!
Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification. Its lead drug candidate, Liposomal Grb2 (BP1001), targets the protein Growth factor receptor-bound protein 2 (Grb2). Its other liposome delivered antisense drug candidate, Liposomal Bcl2 (BP1002), targets the protein B-cell lymphoma 2 (Bcl2). BP1001 is in Phase II clinical trials for acute myeloid leukemia, and for blast phase and accelerated phase chronic myelogenous leukemia. BP1002 is intended to target the lymphoma and certain solid tumor markets. BP1001 is also in preclinical studies for solid tumors, including triple negative breast cancer and inflammatory breast cancer.
This website uses cookies to ensure you get the best experience on our website. To learn more about cookies, including how to control cookies, please read our Cookies Policy.
BPTH
